Genmab — November 2018

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 19:13:40 GMT

transalp — Fri, 30 Nov 2018 19:13:40 GMT

Lyder rigtigt bob, go weekend til dig også..:)

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 18:44:11 GMT

JKY_VH — Fri, 30 Nov 2018 18:44:11 GMT

enig bibob og god weekend:-)

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 18:35:01 GMT

bibob — Fri, 30 Nov 2018 18:35:01 GMT

God weekend til alle. Psykologisk tror jeg det er vigtigt at ugen slutter over kurs 1000. Der er en meget vigtig konference i USA ( ASH ) som helt sikkert vil give nogle svar på mange spørgsmål ift . MAIA . Hvis G20 også kommer med lidt positivt vil vi se en positiv start på næste uge. Der skal ikke så meget til før stemningen skifter. Men lad os være tilfreds med en trods alt tilfredstillende uge.

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 16:15:24 GMT

Darvin — Fri, 30 Nov 2018 16:15:24 GMT

Maybe the Dancing Queen

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 12:15:52 GMT

Bulder — Fri, 30 Nov 2018 12:15:52 GMT

Men man skal være endog meget skeptisk for at udlægge kommentaren negativt for D-Rd.

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 12:14:30 GMT

Bulder — Fri, 30 Nov 2018 12:14:30 GMT

Ja. kommentaren er til D-VMp og som sådan ikke overraskende. det vidste vi i forvejen. Men han siger "combinationS" i flertal. Det eneste der måske kunne tyde på at han mener, i det hele taget.

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 12:04:58 GMT

E_L — Fri, 30 Nov 2018 12:04:58 GMT

Citi said that while bears may point to competitive threats from BCMA and CAR-T therapies, Darzalex is likely to be the “dance/combination partner of choice.” - via Bloomberg - https://www.bloomberg.com/news/articles/2018-11-29/drugmakers-set-for-multiple-myeloma-showdown-at-hematology-event

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 11:51:34 GMT

E_L — Fri, 30 Nov 2018 11:51:34 GMT

Good News Is on the Way for Blood Cancer Patients - Barrons - https://www.barrons.com/articles/good-news-is-on-the-way-for-blood-cancer-patients-1543581000

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 11:47:24 GMT

E_L — Fri, 30 Nov 2018 11:47:24 GMT

i forwarded those Rajkumar comments from last week or so to Rachel, I am sure they are familiar with this discussion. I mean, at the end of the day they can not force anyone to use Dara, but they can debate the benefits and sell it strongly this weekend. I am sure JNJ will do its part.

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 11:44:24 GMT

peter12 — Fri, 30 Nov 2018 11:44:24 GMT

@Sukker 13:22 Kommentaren er til D-VMP ? Som vist ikke bruges i US ?

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 11:36:30 GMT

Sukkeralf — Fri, 30 Nov 2018 11:36:30 GMT

Yes and such a big difference between Jans expectations of capturing 50% of the market quite quick

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 11:35:53 GMT

E_L — Fri, 30 Nov 2018 11:35:53 GMT

the only disadvantage is that the late breaker is on the last day…

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 11:35:06 GMT

E_L — Fri, 30 Nov 2018 11:35:06 GMT

comments like that are exactly why i wrote last week "but given this discussion, i now realise how important it will be to have the late breaker, to explain and discuss with MD's (i thought with this data it would have been a slam dunk"

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 11:23:18 GMT

Sukkeralf — Fri, 30 Nov 2018 11:23:18 GMT

Lets bet and hope Jan is right !!

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 11:22:55 GMT

Sukkeralf — Fri, 30 Nov 2018 11:22:55 GMT

Not that good comment in twitter link: I’d wager this doesn’t translate into Dara-based combinations dominating community practices in the US

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 11:19:39 GMT

Bulder — Fri, 30 Nov 2018 11:19:39 GMT

Well, not nescessarily on Monday, but the week starting with Monday.

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 11:14:04 GMT

Bulder — Fri, 30 Nov 2018 11:14:04 GMT

According to the timeframe request for RTOR is submitted at the time of top line data. Should have been done long time ago After 4 weeks initial RTOR-meting with OCE. This is next monday. Exactly timed with the R&D-day.

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 10:58:43 GMT

E_L — Fri, 30 Nov 2018 10:58:43 GMT

and from what date are you counting? October 29?

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 10:48:57 GMT

gentogen — Fri, 30 Nov 2018 10:48:57 GMT

https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/OCE/ucm612927.htm#ROTR_FAQ_s

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 10:48:18 GMT

gentogen — Fri, 30 Nov 2018 10:48:18 GMT

Ifølge vejledningen fra FDA skal de først søge om det og derefter indsende en foreløbig ansøgning, der så kan blive til en ansøgning. Jeg tvivler lidt på, at de oplyser noget før en eventuel egentlig ansøgning er indsendt, hvilket ifølge standardplanen er ved cirka uge 16

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 10:40:19 GMT

E_L — Fri, 30 Nov 2018 10:40:19 GMT

no, I have asked FDA 2 times via twitter if there is a list of drugs on the RTOR program, but they did not even reply. I can't find anything on the FDA website

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 10:28:24 GMT

Plimsoller — Fri, 30 Nov 2018 10:28:24 GMT

Do we know anything about RTOR?

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 09:27:22 GMT

E_L — Fri, 30 Nov 2018 09:27:22 GMT

https://twitter.com/Mohty_EBMT/status/1068288762680008704

Reply to Genmab — November 2018 on Fri, 30 Nov 2018 09:17:29 GMT

E_L — Fri, 30 Nov 2018 09:17:29 GMT

Mohty https://twitter.com/Mohty_EBMT/status/1068264359397273600